ROCK1 and graft versus host disease: Based on our study, ROCK1/2-inhibition, which is already used in clinical trials for pulmonary arterial hypertension58 and coronary stenosis59, is a promising approach to treat acute SR-GVHD, possibly in combination with ruxolitinib.